STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.
about
Treatment of Metastatic Colorectal Cancer: Standard of Care and Future PerspectivesAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerRole of targeted therapy in metastatic colorectal cancerStudy protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab vImmunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC.
P2860
STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
STRATEGIC-1: A multiple-lines, ...... metastatic colorectal cancer.
@ast
STRATEGIC-1: A multiple-lines, ...... metastatic colorectal cancer.
@en
type
label
STRATEGIC-1: A multiple-lines, ...... metastatic colorectal cancer.
@ast
STRATEGIC-1: A multiple-lines, ...... metastatic colorectal cancer.
@en
prefLabel
STRATEGIC-1: A multiple-lines, ...... metastatic colorectal cancer.
@ast
STRATEGIC-1: A multiple-lines, ...... metastatic colorectal cancer.
@en
P2093
P2860
P1433
P1476
STRATEGIC-1: A multiple-lines, ...... metastatic colorectal cancer.
@en
P2093
Alexandra Hadengue
Armand de Gramont
Benoist Chibaudel
Christophe Tournigand
Dominique Notelet
Franck Bonnetain
Jérôme Paget
Magdalena Benetkiewicz
Marine Hug de Larauze
Thierry André
P2860
P2888
P356
10.1186/S12885-015-1503-7
P407
P577
2015-07-04T00:00:00Z
P5875
P6179
1022619302